Safety Endpoints
Kaletra
and
interferon alfa-2b therapy was well tolerated by the exposed group
without premature discontinuation secondary to
adverse
effects. There
were
no significant differences among the 3 group in the incidence of nausea,
diarrhea, rash, leukopenia, neutropenia, anemia, thrombocytopenia,
increased creatinine, and et al (Table 2). However, the incidence of
increased creatine kinase over the therapy course was higher in the
exposed group (15.91% in interferon alfa-2b group vs 20.90% in
Kaletra/ interferon alfa-2b group) than in the standard care group (0),
despite without statistical difference. Aside from anemia and increased
bilirubin, the occurrence of adverse effects were lower in standard care
group than in therapy groups.